- Home
- ASO vs XENE Comparison
ASO vs XENE Comparison
Compare ASO & XENE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ASO | XENE |
|---|---|---|
| Founded | 1938 | 1996 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Recreational Games/Products/Toys | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 3.2B |
| IPO Year | 2020 | 2014 |
Fundamental Metrics
Financial Performance| Metric | ASO | XENE |
|---|---|---|
| Price | $57.89 | $56.42 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 12 |
| Target Price | $58.08 | ★ $67.17 |
| AVG Volume (30 Days) | ★ 1.3M | 933.9K |
| Earning Date | 06-09-2026 | 05-11-2026 |
| Dividend Yield | ★ 1.03% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 5.54 | N/A |
| Revenue | ★ $6,053,414,000.00 | $311,000.00 |
| Revenue This Year | $5.13 | N/A |
| Revenue Next Year | $5.36 | $2,496.48 |
| P/E Ratio | $10.46 | ★ N/A |
| Revenue Growth | ★ 2.02 | N/A |
| 52 Week Low | $35.95 | $28.19 |
| 52 Week High | $62.45 | $62.91 |
Technical Indicators
Market Signals| Indicator | ASO | XENE |
|---|---|---|
| Relative Strength Index (RSI) | 53.86 | 51.84 |
| Support Level | $57.09 | $52.55 |
| Resistance Level | $60.55 | $56.66 |
| Average True Range (ATR) | 2.47 | 1.79 |
| MACD | 0.26 | -0.47 |
| Stochastic Oscillator | 57.66 | 17.41 |
Price Performance
Historical ComparisonAbout ASO Academy Sports and Outdoors Inc.
Academy Sports and Outdoors Inc is engaged in the full-line sporting goods and outdoor recreation retailer in the United States. The company's product categories are outdoors, apparel, sports & recreation, and footwear.
About XENE Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.